Regorafenib联合TAS102新策略治疗肝细胞癌的研究

doi:10.19401/j.cnki.1007-3639.2021.04.008

中国癌症杂志 ›› 2021, Vol. 31 ›› Issue (4): 294-301.doi: 10.19401/j.cnki.1007-3639.2021.04.008

Regorafenib联合TAS102新策略治疗肝细胞癌的研究

章　俊 ^1,2 ，董宇华³ ，杨　叶 ¹，张梦琪 ¹ ，何　常^1,2

1．贵州医科大学病理学教研室，贵州贵阳 550004 ；
2．贵州医科大学附属医院病理科，贵州贵阳 550004 ；
3．贵州医科大学生理学教研室，贵州贵阳 550004

出版日期:2021-04-30 发布日期:2021-04-29
通信作者: 何常 E-mail: hechang_66@163.com

A novel strategy of regorafenib in combination with TAS102 against hepatocellular carcinoma

ZHANG Jun ^1,2 , DONG Yuhua³ , YANG Ye ¹, ZHANG Mengqi ¹ , HE Chang ^1,2

1.Department of Pathology, Guizhou Medical University, Guiyang 550004, Guizhou Province, China; 2. Department of Pathology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou Province, China; 3. Department of Physiology, Guizhou Medical University, Guiyang 550004, Guizhou Province, China

Published:2021-04-30 Online:2021-04-29
Contact: HE Chang E-mail: hechang_66@163.com

摘要/Abstract

摘要： 背景与目的：瑞格菲尼（regorafenib，REG）和TAS102是治疗消化道肿瘤的新型药物。嘧啶类药物5-氟尿嘧啶（5-fluorouracil，5-FU）联合REG可抑制多药耐药转移性结肠癌的进展。肿瘤干细胞（cancer stem cell，CSC）决定肿瘤的自我更新，异质性及治疗耐受等，靶向CSC为治愈肿瘤提供了可能途径。探讨REG联合TAS102治疗肝细胞癌（hepatocellular carcinoma，HCC）的联合效应及潜在机制。方法：以人HepG2、Huh7和SK-Hep1肝癌细胞系为实验对象。REG和TAS102单药或联合处理肝癌细胞及荷瘤动物。采用细胞计数试剂盒（cell counting kit-8，CCK-8）检测肝癌细胞活力；流式细胞术分析肝癌细胞中CD133阳性细胞亚群比例；采用蛋白质印迹法（Western blot）分析不同药物处理后肝癌细胞中蛋白表达差异；含不同药物的干细胞培养基培养肝癌干细胞球（HCC sphere）；荷瘤动物实验评估药物联合治疗效果。结果：REG及TAS102单药显著抑制肝癌细胞活力。TAS102联合使用减低REG单药时诱导增加的CD133阳性细胞亚群比例及干细胞标志分子SRY相关的高迁移率族盒蛋白-2（SRY-related high mobility group box protein-2，SOX2）和乙醛脱氢酶1A（aldehyde dehydrogenase 1A，ALDH1A）的蛋白水平。同时REG的联合使用下调TAS102单药处理时诱导活化的抗凋亡蛋白髓细胞白血病-1蛋白（myeloid cell leukemia-1，MCL1）信号。REG联合TAS102显著抑制了HCC sphere的形成。动物实验证实REG联合TAS102显著抑制肝癌瘤体的生长。结论：REG联合TAS102通过调控肝癌细胞的干细胞性及抗凋亡信号，发挥联合用药增强抗HCC的活性，为临床治疗难治性HCC提供了一种新的治疗策略。

关键词: 瑞格菲尼, TAS102, 肿瘤干细胞, 联合治疗, 肝细胞癌

Abstract: Background and purpose: Both regorafenib (REG) and TAS102 are novel anti-tumor drugs in the treatment of the digestive cancers. REG in combination with 5-fluorouracil (5-FU), a pyrimidine analogue, could inhibit the progression of multi- drug resistant metastatic colorectal cancer. Cancer stem cells (CSCs) determine tumor self-renewal, heterogeneity and therapeutic resistance, and targeting CSCs provides a curable approach to multiple malignancies. This study aimed to investigate the therapeutic effect and potential mechanism of REG in combination with TAS102 against hepatocellular carcinoma (HCC). Methods: A panel of human liver cancer cell lines HepG2, Huh7 and SK-Hep1 were used in this study. Liver cancer cells and xenograft tumor animals were treated with REG and TAS102 monotherapy or combining regimen. Cell counting kit-8 (CCK-8) was used to assess HCC cell viability. The subpopulations of CD133 positive cells were detected and analyzed using flow cytometry. Western blot was used to evaluate these protein contents in HCC cells with diverse drug treatments. HCC spheres were cultured in growing sphere medium with diverse drugs. Xenograft tumor animals were used to assess the therapeutic effect in vivo. Results: REG or TAS102 monotherapy significantly inhibited HCC cell viability. TAS102 in combination therapy reduced the increase of CD133 + cell subpopulation, SRY-related high mobility group box protein-2 (SOX2) and aldehyde dehydrogenase 1A (ALDH1A) expressions induced by REG alone. Moreover, REG attenuated TAS102-induced myeloid cell leukemia-1 (MCL-1) expression. REG in combination with TAS102 ameliorated the formation of HCC sphere. Animal experiment demonstrated that REG in combination with TAS102 significantly eliminated HCC tumor growth in xenograft animals. Conclusion: REG in combination with TAS102 regulates HCC stemness and MCL-1 signaling and improves the therapeutic effect against HCC. The combination therapy may provide a novel strategy for refractory HCC patients.

Key words: Regorafenib, TAS102, Cancer stem cell, Combination therapy, Hepatocellular carcinoma

章　俊, 董宇华, 杨　叶, 张梦琪, 何　常 . Regorafenib联合TAS102新策略治疗肝细胞癌的研究[J]. 中国癌症杂志, 2021, 31(4): 294-301.

ZHANG Jun , DONG Yuhua , YANG Ye , ZHANG Mengqi , HE Chang . A novel strategy of regorafenib in combination with TAS102 against hepatocellular carcinoma[J]. China Oncology, 2021, 31(4): 294-301.

[1]	李　崴, 张山岭, 陶英杰, 王旭东. T细胞免疫代谢调控与免疫检查点抑制剂联合应用的现状及研究进展[J]. 中国癌症杂志, 2021, 31(7): 640-646.
[2]	肖　锋, 肖静文, 邵建国, 陈丽燕, 顾春燕 . PD-1在肝细胞癌肿瘤浸润淋巴细胞中的表达及与预后的相关性[J]. 中国癌症杂志, 2021, 31(5): 419-427.
[3]	牛　娜, 林岩松 . ⁹⁰ Y微球选择性内放射治疗在肝细胞癌中的应用及研究进展[J]. 中国癌症杂志, 2021, 31(5): 428-434.
[4]	刘　敏, 陈添亮, 郭　娟, 伊雪, 高洪泉, 巫佳翠, 王玉孝 . 蛋白激酶CβⅡ通过IL-6自分泌途径促进肝细胞癌侵袭的研究[J]. 中国癌症杂志, 2021, 31(4): 268-276.
[5]	张　欣, 周　成, 周恺乾, 柏乾明, 蒋冬先, 宿杰阿克苏, 侯英勇, 王　征, 纪　元 . 肉瘤样肝细胞癌中MET基因扩增与预后的相关性分析[J]. 中国癌症杂志, 2020, 30(9): 641-649.
[6]	徐珊珊 , 宋琴琴 , 仵红娇 , 付　宁 , 车玲玉 , 金　敏 , 刘　冲 , 韩素桂 , 张雪梅 , 张　志 . 膜辅助蛋白CD46 rs1970530遗传变异对肝癌发病风险的影响[J]. 中国癌症杂志, 2020, 30(9): 656-660.
[7]	皮思蝶, 郑小川, 毛彬力, 崔　静, 胡　源. SAMHD1通过调控p27表达抑制肝细胞癌细胞增殖的研究[J]. 中国癌症杂志, 2020, 30(7): 489-496.
[8]	蒙秋华, 田　婧, 覃　妍, 蒙秋晓, 董　敏. 蛋白酪氨酸磷酸酶受体D通过STAT3途径影响肝癌细胞PD-L1表达的机制研究[J]. 中国癌症杂志, 2020, 30(4): 261-267.
[9]	王　洁. 免疫检查点抑制剂在肺癌治疗应用中的挑战与方向[J]. 中国癌症杂志, 2020, 30(10): 744-749.
[10]	李国雨 , 何　明 . 广泛期小细胞肺癌免疫联合治疗研究的新进展[J]. 中国癌症杂志, 2020, 30(10): 826-833.
[11]	虞　梅,梅　琪,韩莹莹,翟凌云,沙红芳,徐祥勇,倪　娟,崔建巍,丁　红 . 超声造影灌注时相分析在监控肝硬化结节演变和恶变中的临床价值[J]. 中国癌症杂志, 2019, 29(9): 709-714.
[12]	马家强，曹春梅，Shyamal Goswami,陈　沁，高　强，张晓明. 肝细胞癌组织ICOS+T细胞的多重免疫组织化学检测及其预后价值研究[J]. 中国癌症杂志, 2019, 29(5): 352-361.
[13]	李懿皞，戴　谦，王蓓丽，潘柏申，郭　玮. 肝肿瘤细胞干性与糖代谢特点的相关性研究[J]. 中国癌症杂志, 2019, 29(10): 773-779.
[14]	彭雪强,杨　良,张小东,等. 自噬相关基因5在肝癌组织中的表达及临床意义[J]. 中国癌症杂志, 2018, 28(5): 321-326.
[15]	马荣,朱辉,龚建平. 基于倾向性评分匹配法的经导管肝动脉化疗栓塞联合高强度聚焦超声治疗肝癌的生存情况分析[J]. 中国癌症杂志, 2018, 28(4): 282-289.

Regorafenib联合TAS102新策略治疗肝细胞癌的研究

A novel strategy of regorafenib in combination with TAS102 against hepatocellular carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价